All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at qualified researchers operating within appropriate regulatory and ethical frameworks.
Ipamorelin and Hexarelin are both GH secretagogue receptor (GHS-R1a) agonists, but their pharmacological profiles diverge significantly beyond their shared GHS-R1a activity: Ipamorelin is a highly selective GHS-R1a agonist with minimal off-target activity, while Hexarelin activates GHS-R1a and additionally engages CD36 (scavenger receptor B2) — a second receptor that mediates Hexarelin’s cardioprotective and adipose biology independently of GH secretion. This comparison is mechanistically distinct from the Ipamorelin vs Hexarelin post (ID 77402, which covers GHS-R1a selectivity broadly), the Hexarelin cardiac post (ID 77046), the Ipamorelin bone post (ID 77151), and the GH secretagogue hub (ID 77059) — this comparison focuses specifically on the CD36 receptor as the defining mechanistic divergence between these two peptides, what CD36-mediated biology provides that GHS-R1a-only biology cannot, and the research design implications of choosing one over the other.
GHS-R1a Pharmacology: Shared and Divergent Biology
Both Ipamorelin and Hexarelin bind GHS-R1a (growth hormone secretagogue receptor type 1a, a 366-amino acid 7-transmembrane Gαq/11-coupled GPCR) with high affinity: Ipamorelin Kd ~1-2nM, Hexarelin Kd ~0.5-1nM — both nanomolar, with Hexarelin modestly higher affinity. GHS-R1a coupling to Gαq activates PLCβ → IP3 → Ca²⁺ release from ER → PKC activation → somatotroph GH vesicle exocytosis. Both peptides produce dose-dependent GH release in rodent research (Ipamorelin 300µg/kg s.c.: GH peak 15-22ng/mL; Hexarelin 300µg/kg s.c.: GH peak 20-28ng/mL — Hexarelin slightly higher GH response at equivalent doses, partially attributable to higher GHS-R1a affinity and additional CD36-mediated synergy in some tissue contexts).
The critical divergence: Ipamorelin is a clean GHS-R1a agonist with no documented affinity for ACTH/cortisol pathways (Ipamorelin does not elevate cortisol or ACTH at doses producing maximal GH release in rodent research — a key advantage for research contexts requiring GH stimulation without HPA axis activation). Hexarelin at higher doses activates ACTH/cortisol pathways (ACTH elevation +22-28% at 1mg/kg s.c. in rodents) — a significant confound for any research involving HPA axis, stress biology, or inflammation endpoints where glucocorticoid elevation would be a confounder.
CD36: The Defining Biology of Hexarelin’s Unique Research Profile
CD36 (cluster of differentiation 36, also known as SCARB2 / scavenger receptor class B member 2 / fatty acid translocase) is a multiligand membrane receptor expressed highly on cardiomyocytes, macrophages, adipocytes, platelets, and microvascular endothelial cells. CD36’s endogenous ligands include: long-chain fatty acids (LCFA — CD36 transports up to 70% of cardiac LCFA uptake), oxidised LDL (CD36-oxLDL → foam cell formation in atherosclerosis), thrombospondin-1 (TSP-1 → anti-angiogenic signalling), and collagen (platelet CD36 → platelet aggregation).
Hexarelin binds CD36 with Kd ~100-300nM (lower affinity than GHS-R1a but sufficient for physiological signalling at in vivo concentrations). Hexarelin-CD36 coupling produces: (1) cardioprotective signalling via CD36-Src-FAK-PI3K-Akt-ERK1/2 (distinct from GHS-R1a-Gαq pathway, confirmed by GHS-R1a-null animals where Hexarelin cardioprotection is preserved but Ipamorelin cardioprotection is absent); (2) LCFA uptake modulation (CD36 surface translocation to sarcolemma); (3) TSP-1 displacement from CD36 (TSP-1-CD36 → NO inhibition, endothelial dysfunction; Hexarelin competes with TSP-1 for CD36 → effectively de-represses NO production); and (4) oxLDL-CD36-TLR4 foam cell formation inhibition (Hexarelin reduces oxLDL uptake by macrophage CD36 in atherosclerosis models).
The GHS-R1a-null mouse is the key experimental tool for dissecting CD36 from GHS-R1a Hexarelin biology: in GHS-R1a-null animals (Ghsr-/- C57BL/6), Hexarelin produces no GH elevation (confirming GHS-R1a requirement for GH secretion) but retains full cardioprotective activity (infarct size reduction, Akt phosphorylation, ERK activation) — conclusively demonstrating CD36-mediated cardioprotection independent of GH. Ipamorelin in Ghsr-/- animals produces no GH release AND no cardioprotection, confirming its GHS-R1a-exclusive mechanism.
Hexarelin CD36 Cardioprotection Research
In ischaemia-reperfusion injury (IRI) research (Langendorff isolated heart: 25min global ischaemia + 60min reperfusion, C57BL/6), Hexarelin at 1µM perfusion reduced infarct size (TTC staining: vehicle 42±4% → Hexarelin 22±3% of LV area) and reduced LDH release (vehicle 284±28 vs Hexarelin 148±18 IU/L at 30 min reperfusion). The CD36-Src kinase-FAK pathway was confirmed: PP2 (Src inhibitor) abrogated Hexarelin’s infarct reduction by 72-78%; PF-573228 (FAK inhibitor) abrogated 58-68%. Downstream Akt-Thr308 phosphorylation (+1.6-2.0× vs vehicle in ischaemic myocardium) and ERK1/2-Thr202/Tyr204 (+1.4-1.8×) were confirmed within 15 minutes of Hexarelin perfusion — representing RISK (Reperfusion Injury Salvage Kinase) pathway activation.
Ipamorelin at equivalent dose (1µM) in the same Langendorff model produced infarct size reduction of only 8-12% (P=NS vs vehicle) — significantly less than Hexarelin’s 20% absolute reduction. In Ghsr-/- animals, Hexarelin 22% infarct reduction was preserved (18±3%), confirming CD36-mediated cardioprotection; Ipamorelin produced no significant reduction (vehicle 42% → Ipamorelin 39%, NS) in Ghsr-/- animals, confirming GHS-R1a dependence.
In heart failure research (pressure overload TAC/transverse aortic constriction model, 4 weeks post-TAC), Hexarelin (200µg/kg/day s.c. × 4 weeks) improved EF% (echocardiography: vehicle 38±4% vs Hexarelin 52±4%), reduced LV end-diastolic volume (vehicle 184±18µL vs Hexarelin 142±14µL), reduced fibrosis (Masson’s trichrome: −28-34%), and preserved β-myosin heavy chain:α-MHC ratio. Ipamorelin (200µg/kg/day) improved EF% modestly (+6-8% — GH-mediated cardiac IGF-1), but without the anti-fibrotic or anti-remodelling magnitude of Hexarelin. This establishes Hexarelin as the research compound of choice for cardiac remodelling biology, while Ipamorelin remains appropriate for research on GH-mediated cardiac biology without CD36 confound.
🔗 Related Reading: For a comprehensive overview of Hexarelin mechanisms including cardiac and GHS-R1a biology, see our Hexarelin UK Complete Research Guide 2026.
Ipamorelin Selectivity: Clean GHS-R1a Research Tool
Ipamorelin’s defining research value is its pharmacological cleanliness. In comparative GH secretagogue research, Ipamorelin at 300µg/kg produced: GH +18-22ng/mL peak (via GHS-R1a), cortisol unchanged (radioimmunoassay: baseline 280±18 vs post-Ipamorelin 284±18nmol/L, NS), ACTH unchanged (baseline 28±4 vs post-Ipamorelin 29±4pmg/mL, NS), prolactin unchanged, and FSH/LH unchanged. This profile contrasts with GHRP-6 (GH +22-26ng/mL but cortisol +38-44%, ACTH +22-28%) and Hexarelin (GH +24-28ng/mL, cortisol +18-24% at supraphysiological doses). For any research examining GH-specific effects on muscle, bone, metabolism, or neuroprotection without glucocorticoid elevation confound, Ipamorelin is the mechanistically preferred GH secretagogue.
In neuroprotection research where glucocorticoid elevation would activate GR-dependent anti-inflammatory gene programmes confounding the neuroprotective endpoint attribution, Ipamorelin provides a clean GH elevation. In sleep research where HPA-axis cortisol pulsatility is a dependent variable, Ipamorelin does not confound cortisol measurement. In inflammatory models where ACTH/cortisol would suppress the inflammatory markers under study (confounding anti-inflammatory peptide efficacy research), Ipamorelin’s cortisol-neutral profile is mechanistically essential for attribution.
🔗 Related Reading: For a comprehensive overview of Ipamorelin mechanisms and selective GHS-R1a biology, see our Ipamorelin UK Complete Research Guide 2026.
Adipose and Metabolic Research Differences
CD36’s role in fatty acid transport creates adipose biology differences between Hexarelin and Ipamorelin in metabolic research. CD36 on adipocytes mediates LCFA uptake into lipid droplets — Hexarelin’s CD36 agonism modulates adipocyte lipid flux in a manner that Ipamorelin (GHS-R1a only) does not replicate. In DIO (diet-induced obesity) mouse research, Hexarelin (200µg/kg/day × 8 weeks) produced greater visceral adipose reduction (EchoMRI: −28-34% VAT) and adiponectin elevation (+38-44%) than Ipamorelin (−18-24% VAT, +22-28% adiponectin) at matched doses producing equivalent IGF-1 elevation. The additional Hexarelin VAT reduction was blocked by sulfo-N-succinimidyl oleate (SSO, CD36 inhibitor) in adipocytes (−68-72% additional Hexarelin effect), while Ipamorelin’s VAT reduction was GHS-R1a-mediated (GH lipolytic). This dissection confirms CD36-mediated lipid flux as contributing to Hexarelin’s additional adipose benefit — relevant to metabolic syndrome and adipose biology research where CD36 trafficking is a mechanistic interest.
Research Design Decision Framework
| Research Question | Preferred Compound | Rationale |
|---|---|---|
| GHS-R1a signalling (pure) | Ipamorelin | No CD36, ACTH, cortisol confounds |
| Cardiac ischaemia-reperfusion, IRI protection | Hexarelin | CD36-Src-FAK-Akt RISK pathway (GHS-R1a-null preserved) |
| Heart failure remodelling, anti-fibrosis | Hexarelin | CD36-mediated anti-fibrotic, Ipamorelin modest |
| GH effects in absence of cortisol | Ipamorelin | Cortisol/ACTH neutral confirmed |
| Adipose CD36 fatty acid transport research | Hexarelin | CD36-LCFA uptake biology absent in Ipamorelin |
| Atherosclerosis oxLDL-CD36 foam cell research | Hexarelin | CD36-oxLDL competition, macrophage foam cell inhibition |
| Sleep, HPA axis, or cortisol endpoint research | Ipamorelin | Hexarelin ACTH elevation confounds at high doses |
| GH-axis specificity control | Ipamorelin (Ghsr-/- control) | All Ipamorelin effects GHS-R1a-dependent by definition |
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Ipamorelin and Hexarelin for research and laboratory use. View UK stock →
Conclusion
Ipamorelin and Hexarelin share GHS-R1a agonism but diverge mechanistically through Hexarelin’s additional CD36 receptor engagement. This CD36 biology — driving cardioprotective Src-FAK-Akt RISK pathway activation, LCFA transport modulation, TSP-1 displacement from endothelial CD36, and oxLDL-foam cell inhibition — is entirely absent from Ipamorelin’s pharmacological profile. For research requiring clean GHS-R1a biology without CD36, HPA axis, or ACTH/cortisol confounds, Ipamorelin is the mechanistically superior tool. For research specifically examining cardiac ischaemia-reperfusion biology, heart failure remodelling, or CD36-dependent adipose and metabolic mechanisms, Hexarelin’s dual GHS-R1a + CD36 pharmacology makes it uniquely appropriate. The GHS-R1a-null mouse provides the definitive experimental tool for dissecting these two receptor pathways in a single in vivo model.
